Mid-Capacity Triple-Agonist Vial (15mg)

Retatrutide (15mg) is supplied in Australia by Daza Enhanced with fast domestic shipping to all states and territories.

The 15mg vial sits between the 10mg and 20mg formats — suitable for mid-length research protocols. Better value per milligram than the 10mg vial.

Retatrutide’s triple-receptor activity distinguishes it from other compounds in weight-loss research. Phase 2 clinical trials reported a mean body weight reduction of up to 24% over 48 weeks — outperforming semaglutide and tirzepatide in head-to-head comparisons. The mechanism targets three pathways simultaneously: appetite regulation via GLP-1, fat metabolism and insulin sensitivity via GIP, and increased energy expenditure via glucagon receptor activation.

Key Research Areas

• Fat Loss Research — including visceral adiposity
• Appetite Regulation — reduced food intake and caloric studies
• Metabolic Markers — blood pressure, lipids, waist circumference
• Energy Expenditure — via glucagon receptor activation
• Comparative Research — outperforms semaglutide and tirzepatide in head-to-head data

Supplied as lyophilized powder at ≥99% purity, verified by HPLC and mass spectrometry. 15mg per vial. Fast domestic shipping across Australia, with batch-specific CoA information available in our CoA Library.

⚠ For in-vitro research and laboratory use only. Not for human consumption.